Morbidity and mortality of parathyroid surgery – a retrospective analysis

Česká verzia

Authors: J. Astl ^1,2; J. Hložek ¹ ; R. Holý ¹; J. Rotnágl ¹
Authors place of work: Klinika otorinolaryngologie a maxilofaciální chirurgie 3. lékařské fakulty Univerzity Karlovy, Ústřední vojenská, nemocnice, Praha ¹; Katedra otorinolaryngologie, Institut postgraduálního vzdělávání ve zdravotnictví Praha, Fakultní nemocnice Motol, Praha ²
Published in the journal: Rozhl. Chir., 2021, roč. 100, č. 3, s. 126-132.
Category: Původní práce
doi: https://doi.org/10.33699/PIS.2021.100.3.126–132

Summary

Introduction: The incidence of parathyroid – glandula parathyreoideae (PTG) diseases has been increasing worldwide. Unlike benign tumours, the incidence of malignant PTG tumours is rather a rare diagnosis. The morbidity of parathyroid surgery is associated with surgical removal of one or more pathologically altered parathyroid glands, particularly parathyroid adenoma associated with primary hyperparathyroidism (HPPT), but also hyperplasia associated with secondary or tertiary HPPT, and last but not least, HPPT due to parathyroid cancer.

Methods: A retrospective statistical analysis was performed in the set of patients undergoing surgery for a parathyroid disorder at the Department of Otorhinolaryngology and Maxillofacial Surgery, 3^rd Faculty of Medicine, Charles University and Military University Hospital in Prague in 2013–2019 (7-year period). In this period, 127 procedures were performed. The incidences of morbidity, mortality, complications and lethality were analysed.

Results: Parathyroid surgery was performed in 20 male and 107 female patients. The mean age was 54.7 years, and the morbidity expressing recurrent laryngeal nerve (RLN) palsy was 0.7% of the nerves exposed during the procedure. The incidence of permanent normal postoperative calcaemia was 98.43%, demonstrated by a decrease in serum parathyroid hormone (PTH) levels. In 12 cases, this state was achieved only after a surgical revision (primary procedure for primary HPPT in 2 cases; 10 patients came for surgical revision with secondary or tertiary HPPT from other centres). Decreased PTH levels were demonstrated intraoperatively in 12.6% patients using the so-called PTH assay (a rapid serum PTH assay). Surgery for secondary or tertiary hyperparathyroidism was done in 33 patients (26% procedures). PTG surgery lethality (mortality) was divided into perioperative mortality within 24 hours from the procedure and early mortality within 120 hours. Lethality related to PTG surgery was 0.0% including patients undergoing the surgery while being in a dialysis programme and those with kidney transplant.

Conclusions: Surgery is always associated with complications, with morbidity and mortality. Experience of endocrinology surgeons of all specialties is reflected in a very low incidence of RLN injuries and in sufficient oncological, or respectively, surgical radicality. This, in connection with other medical fields of endocrinology, nephrology, transplantology, nuclear medicine and oncology, allows a safe and effective treatment of all PTG disorders with a good prognosis for the patients. In those with secondary or tertiary HPPT, it not only improves their quality of life, which was not explored in our study, but in many cases it is an essential step for listing the patient for the transplant surgery. The current level of experience in the field of parathyroid carcinoma does not enable us to formulate any conclusions in terms of prognosis which should be considered as very serious in all cases.

Keywords:

parathyroid glands – surgery – complications − morbidity − mortality

Zdroje

Machado NM, Scott MW. Parathyroid cancer: A review. Cancers (Basel). 2019;11(11):1676. Published online 2019 Oct. 28. doi:10.3390/cancers11111676.
Adámek S, Libánský P, Lischke R, et al. Chirurgická léčba primární hyperparathyreózy v kontextu ortopedické diagnostiky a léčby: naše zkušenosti u 441 pacientů. Acta Chir Ortop Traumat Czechoslov. 2011;78(4):355–360.
Liu ME, Qiu NC, Zha SL, et al. To assess the effects of parathyroidectomy (TPTX Versus TPTX+AT) for secondary hyperparathyroidism in chronic renal failure: A systematic review and meta-analysis. Int J Surg. 2017;44:353−362. doi:10.1016/j.ijsu.2017.06.029. Epub 2017 Jun 17.
Machado NN, Wilhelm SM. Diagnosis and evaluation of primary hyperparathyroidism. Surg Clin North Am. 2019;99(4):649−666. doi: 10.1016/j.suc.2019.04.006.
Carly SE, Roberts MM, Virji MA, et al. Elevated serum parathormone level after „concise parathyroidectomy“ for primary sporadic hyperparathyroidism. Surgery 2002;132(6):1086−10892; discussion 1092−1093. doi:10.1067/msy.2002.128479.
Yong TY, Li JY. Mediastinal parathyroid carcinoma presenting with severe skeletal manifestations. J Bone Miner Metab. 2010;28(5):591−594. doi:10.1007/s00774-010-0173-4.
Libánský P, Astl J, Adámek S, et al. Surgical treatment of primary hyperparathyroidism in children: report of 10 cases. Int J Pediatr Otorhinolaryngol. 2008;72(8):1177−1182. doi:10.1016/j.ijporl.2008.04.005.
Libánský P, Broulík P, Křížová J, et al. Význam předoperačních a peroperačních lokalizačních vyšetření u primární hyperparathyreózy. DMEV 2006;2:78−82.
Irvin GL. American Association of Endocrine Surgeons. Presidential address: chasin’ hormones. Surgery 1999;126:993−997.
Vaghaiwalla TM, Khan ZF, Lew JI. Review of intraoperative parathormone monitoring with the miami criterion: A 25-year experience. World J Surg Proced. 2016;6(1):1−7. Published online Mar 28, 2016. doi:10.5412/wjsp.v6.i1.1.
Astl J. Chirurgická léčba onemocnění štítné žlázy. Praha, Maxdorf Jessenius 2006.
Fowler GE, Chew PR, Lim CCB, et al. Is there a role for routine laryngoscopy before and after parathyroid Surgery? Surgeon 2019;17(2):102−106. doi:10.1016/j.surge.2018.08.002.
Fewins J, Simpson CB, Miller FR. Complications of thyroid and parathyroid surgery. Otolaryngol Clin North Am. 2003;36(1):189−206, doi:10.1016/s0030-6665(02)00129-9.
Udelsman R. Primary hyperparathyroidism. Curr Treat Options Oncol. 2001;2(4):365−372. doi:10.1007/s11864-001-0030-8.
Schneider R, Slater EP, Karakas E, et al. Initial parathyroid surgery in 606 patients with renal hyperparathyroidism. World J Surg. 2012;36(2):318–326. doi:10.1007/s00268-011-1392-0.
Adamek S, Libansky P, Nanky O, et al. Chirurgische Therapie des primären Hyperparathyreoidismus und dessen Komplikationen: Erfahrungen an 453 Patienten. Zentralbl Chir. 2005;130(2):109−113. doi:10.1055/s-2005-836365.
Borot S, Lapierre V, Carnaille B, et al. Results of cryopreserved parathyroid autografts: a retrospective multicenter study. Surgery 2010;147(4):529−535. doi:10.1016/j.surg.2009.10.010.
Bubeníček P, Kobylka P, Povýšil C, et al. Viabilita tkáně příštítných tělísek měřená průtokovou cytometrií. Čas Lék Čes. 2003;147(10):620−624.
Mazzaglia PJ, Milas M, Berber E, et al. Normalization of 2-week postoperative parathyroid hormone values in patients with primary hyperparathyroidism: four-gland exploration compared to focused-approach surgery. World J Surg. 2010;34(6):1318−1324. doi: 10.1007/s00268-010-0557-6.
Caldwell M, Laux J, Clark M, et al. Persistently elevated PTH after parathyroidectomy at one year: Experience in a tertiary referral center. The Journal of Clinical Endocrinology & Metabolism 2019;104(10):4473–4480, https://doi.org/10.1210/jc.2019-00705.